The American Journal of Medicine
Volume 120, Issue 5 , Pages 435-441 , May 2007

Comparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy

  • Donald P. Tashkin, MD

      Affiliations

    • Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif
    • Corresponding Author InformationRequests for reprints should be addressed to Donald P. Tashkin, MD, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095-1690.
    • ,
  • Gerald L. Klein, MD

      Affiliations

    • Talecris Biotherapeutics, Inc., Research Triangle Park, NC
    • Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Science, Stockton, Calif
    • ,
  • Shoshana S. Colman, PhD

      Affiliations

    • Quintiles Strategic Research Services, San Francisco, Calif
    • ,
  • Hany Zayed, PhD

      Affiliations

    • Quintiles Strategic Research Services, San Francisco, Calif
    • ,
  • Warren H. Schonfeld, PhD

      Affiliations

    • Santa Rosa, Calif.

References 

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2005 Update. National Institutes of Health/WHO. Available at: http://www.goldcopd.com/. Accessed August 23, 2005.
  2. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  3. Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration. 1998;65:354–362
  4. Tashkin D, Bleecker E, Braun S, et al. Results of a mulitcenter study of nebulized inhalant bronchodilator solutions. Am J Med. 1996;100(Suppl 1):S62–S69
  5. Levin D, Little K, Laughlin KR, et al. Addition of anticholinergic soultion prolongs bronchodilator effect of β2 agonists in patients with chronic obstructive pulmonary disease. Am J Med. 1996;100(Suppl 1):S40–S48
  6. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest. 1995;107:401–405
  7. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone (An 85-day multi-center trial). Chest. 1994;105:1411–1419
  8. Balzano G, Battiloro R, Biraghi M, et al. Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chnronic airflow obstruction: metered dose inhaler versus jet nebulizer. J Aerosol Med. 2000;13:25–33
  9. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335–371
  10. Van Beerendonk I, Mesters I, Mudde AN, et al. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. 1998;35:273–279
  11. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123:659–664
  12. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25–31
  13. Dahl R, Greefhorst L, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disesase. Am J Respir Crit Care Med. 2001;164:778–784
  14. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1:165–172
  15. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1557–1565
  16. Barta S, Crawford A, Roberts C. Survey of patients’ views of domiciliary nebuliser treatment for chronic lung disease. Respir Med. 2002;96:375–381

PII: S0002-9343(06)01068-0

doi: 10.1016/j.amjmed.2006.07.043

The American Journal of Medicine
Volume 120, Issue 5 , Pages 435-441 , May 2007

Article Tools